Acrivon Therapeutics, Inc.
ACRV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781174
In the last 90 days, Acrivon Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 46 institutions reported holding it in 13F filings for Q2 2026, worth $38.1M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Acrivon Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 0 | 18 | +18 |
| Shares | 0 | 15.0M | +15.0M |
| Value | $0 | $170.4M | +$170.4M |
New holders (18)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ra Capital Management, L.P. | 4,810,508 | $55.4M | 1.12% |
| Perceptive Advisors LLC | 3,007,858 | $34.7M | 1.00% |
| Sands Capital Ventures, LLC | 1,652,605 | $19.0M | 5.21% |
| Citadel Advisors LLC | 1,634,104 | $18.2M | 0.02% |
| Marshall Wace, LLP | 1,223,252 | $14.1M | 0.04% |
| Wellington Management Group LLP | 900,149 | $9.99M | 0.00% |
| Federated Hermes, Inc. | 823,300 | $9.48M | 0.03% |
| NEA Management Company, LLC | 481,677 | $4.44M | 0.25% |
| HealthCor Management, L.P. | 284,201 | $3.27M | 3.00% |
| Bank of Montreal | 42,444 | $545.0K | 0.00% |
| Goldman Sachs Group Inc | 38,800 | $447.0K | 0.00% |
| Two Sigma Investments, LP | 21,534 | $248.1K | 0.00% |
| Millennium Management LLC | 19,639 | $226.0K | 0.00% |
| DAFNA Capital Management LLC | 15,648 | $180.3K | 0.05% |
| UBS Group AG | 4,748 | $54.7K | 0.00% |
| Barclays PLC | 4,142 | $47.7K | 0.00% |
| Morgan Stanley | 869 | $10.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 159 | $2.00K | 0.00% |
Sold out (0)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
None.